Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938638 | 1.00 | CYP1A2 (0.31) | CYP1A2SMN1; SMN2 | |
| SCHEMBL31093808 | 0.80 | — | — | |
| SCHEMBL7835774 | 0.78 | — | — | |
| SCHEMBL26512086 | 0.73 | CDC25B (0.39) | CYP1A2SMN1; SMN2 | |
| SCHEMBL161716 | 0.71 | NOS2 (0.33) | CYP1A2SMN1; SMN2 | |
| SCHEMBL29412512 | 0.69 | CA12 (0.32) | — | |
| SCHEMBL449368 | 0.69 | — | — | |
| Quinoline SCHEMBL9665224 | 0.69 | ALDH1A1 (0.53) | CYP1A2SMN1; SMN2 | |
| SCHEMBL2630611 | 0.68 | CCR1 (0.50) | SMN1; SMN2 | |
| SCHEMBL17529294 | 0.67 | MAPT (0.48) | CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036690-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 马应龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-119654316-A | Thioglutarimide isoindolinone skeleton-based compound and application thereof | 标新生物医药科技(上海)有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-122036690-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 马应龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| CN-114585609-B | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| CN-115260189-A | Synthetic method of 3-ethyl-7- (hydroxymethyl) -1,5-naphthyridin-2 (1H) -ketone | 爱斯特（成都）生物制药股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | CYP1A2 1223/4885SMN1; SMN2 582/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | CYP1A2 1223/4885SMN1; SMN2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.